NNCS.F Stock Overview
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nanosonics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.87 |
| 52 Week High | AU$3.78 |
| 52 Week Low | AU$1.81 |
| Beta | 1.59 |
| 1 Month Change | 0% |
| 3 Month Change | -33.92% |
| 1 Year Change | -45.95% |
| 3 Year Change | -61.52% |
| 5 Year Change | -43.84% |
| Change since IPO | 94.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNCS.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | -46.0% | -0.7% | 24.7% |
Return vs Industry: NNCS.F underperformed the US Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: NNCS.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| NNCS.F volatility | |
|---|---|
| NNCS.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NNCS.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NNCS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 482 | Michael Kavanagh | www.nanosonics.com.au |
Nanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company manufactures and distributes the trophon ultrasound probe disinfector, and its related consumables and accessories, as well as research, develops, and commercialize of infection control and decontamination products and related technologies. Its product portfolio includes trophon2 that provides protection across various level disinfection HLD cycle; Nanosonics AuditPro, an infection control workflow compliance management; Trophon EPR for mitigating the risk of exposure to toxic chemicals; and CORIS, an instrument reprocessing product platform.
Nanosonics Limited Fundamentals Summary
| NNCS.F fundamental statistics | |
|---|---|
| Market cap | US$526.38m |
| Earnings (TTM) | US$10.09m |
| Revenue (TTM) | US$105.57m |
54.3x
P/E Ratio5.2x
P/S RatioIs NNCS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNCS.F income statement (TTM) | |
|---|---|
| Revenue | AU$164.07m |
| Cost of Revenue | AU$34.34m |
| Gross Profit | AU$129.73m |
| Other Expenses | AU$114.04m |
| Earnings | AU$15.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.052 |
| Gross Margin | 79.07% |
| Net Profit Margin | 9.56% |
| Debt/Equity Ratio | 0% |
How did NNCS.F perform over the long term?
See historical performance and comparison